Pembrolizumab for treating persistent, recurrent, or metastatic cervical cancer

Published on 02 Jan 2024
Last Updated on 02 Jan 2024

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended pembrolizumab for inclusion on the MOH List of Subsidised Drugs, when used in combination with chemotherapy, with or without bevacizumab, for the treatment of persistent, recurrent, or metastatic cervical cancer in patients whose tumours express programmed death-ligand 1 with a combined positive score greater than or equal to 1. The decision was based on the uncertain extent of clinical benefit and unfavourable cost-effectiveness of pembrolizumab at the price proposed by the company.

Clinical indications, subsidy class and MediShield Life claim limit for pembrolizumab are provided in the Annex.

Pembrolizumab for treating persistent, recurrent, or metastatic cervical cancer (Published 2 Jan 2024) [PDF, 306 KB]

PES Pembrolizumab for treating advanced cervical cancer (Published 2 Jan 2024) [PDF, 85 KB]